Dr. Anitua at the symposium

The Basque company BTI Biotechnology Institute has presented its latest advances in the field of regenerative medicine and oral implantology related to the application of Plasma Rich in Growth Factors (PRGF), including a new technique to obtain PRGF and a clinical trial regarding its use to treat arthrosis and other joint injuries.

PRGF technology employs an autologous material (created from the patient's own blood so it does not have any adverse effects) for its application in several therapeutic areas such as oral implantology, oral and maxillofacial surgery, orthopaedics, ophthalmology, sports medicine, the treatment of chronic ulcers and dermatology.

BTI showcases a new system to obtain plasma rich in growth factors (PRGF-ENDORET) simplifying its procurement and reducing preparation times, thus minimising the risks of technical errors and improving reproducibility. "This is a new milestone in the stimulation and regeneration of many tissues. The versatility of this technology, related to its ability to interact with multiple biomaterials, facilitates its application in a growing number of pathological situations", stated Gorka Orive, BTI R&D Manager.

This system and other research projects were presented in the framework of the VIII International Symposium on Oral Implantology, hosted by BTI Biotechnology Institute in October in Bilbao. This event was also the scene for the presentation of the positive preliminary results of a randomised and blinded PRGF clinical trial for the treatment of arthrosis and other joint injuries. The multi-centre clinical trial, directed by orthopaedic surgeon Mikel Sánchez, a specialist in the treatment of elite athletes, included 180 patients and over 1,500 infiltrations.